Year: 1976
Type: article
Study design: Clinical Trial
Abstract: Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/m2 was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and 3/8 renal adenocarcinomas. The i.m. route is less likely to casue pulmonary toxicity or hypotension than the i.v. route. Advanced age and total doses exceeding 200 mg were associated with a higher risk of lung toxicity. All responders had shown at least improvement upon receiving 200 mg; higher total doses should be used only in responding patients.
Source: Cancer
Institutions: University of Kansas Medical Center, United States Air Force, The University of Texas MD Anderson Cancer Center, The University of Texas System, University of Arkansas Medical Center, St. Luke's Mountain States Tumor Institute, Henry Ford Hospital, Wayne State University, The Ohio State University, SWOG Cancer Research Network
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2003754477